Literature DB >> 21091014

Vitreous proteomics and diabetic retinopathy.

Saloni Walia1, Allen C Clermont, Ben-Bo Gao, Lloyd Paul Aiello, Edward P Feener.   

Abstract

Diabetic retinopathy is the major cause of acquired blindness in working-age adults. Studies of the vitreous proteome have provided insights into the etiology of diabetic retinopathy and suggested potential molecular targets for treatments. Further characterization of the protein changes associated with the progression of this disease may suggest additional therapeutic approaches as well as reveal novel factors that may be useful in predicting risk and functional outcomes of interventional therapies. This article provides an overview of the various techniques used for proteomic analysis of the vitreous and details results from various studies evaluating vitreous of diabetic patients using the proteomic approach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091014      PMCID: PMC4996366          DOI: 10.3109/08820538.2010.518912

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  33 in total

Review 1.  Protein identification by mass spectrometry: issues to be considered.

Authors:  Michael A Baldwin
Journal:  Mol Cell Proteomics       Date:  2003-11-06       Impact factor: 5.911

Review 2.  Protein arrays in functional genome research.

Authors:  Christian Maercker
Journal:  Biosci Rep       Date:  2005 Feb-Apr       Impact factor: 3.840

Review 3.  Proteomics by mass spectrometry: approaches, advances, and applications.

Authors:  John R Yates; Cristian I Ruse; Aleksey Nakorchevsky
Journal:  Annu Rev Biomed Eng       Date:  2009       Impact factor: 9.590

4.  Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole.

Authors:  Toyofumi Nakanishi; Reiko Koyama; Tsunehiko Ikeda; Akira Shimizu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-08-25       Impact factor: 3.205

5.  Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients.

Authors:  Taeoh Kim; Sang Jin Kim; Kyunggon Kim; Un-Beom Kang; Cheolju Lee; Kyong Soo Park; Hyeong Gon Yu; Youngsoo Kim
Journal:  Proteomics       Date:  2007-11       Impact factor: 3.984

6.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

Review 7.  The chemical morphology of the vitreous.

Authors:  J E Scott
Journal:  Eye (Lond)       Date:  1992       Impact factor: 3.775

8.  Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders.

Authors:  Y Katsura; T Okano; M Noritake; H Kosano; H Nishigori; S Kado; T Matsuoka
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

Review 10.  Mass spectrometry-based label-free quantitative proteomics.

Authors:  Wenhong Zhu; Jeffrey W Smith; Chun-Ming Huang
Journal:  J Biomed Biotechnol       Date:  2009-11-10
View more
  13 in total

Review 1.  Future opportunities in diabetic retinopathy research.

Authors:  Thomas W Gardner; Emily Y Chew
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

2.  Translational vitreous proteomics.

Authors:  Vinit B Mahajan; Jessica M Skeie
Journal:  Proteomics Clin Appl       Date:  2013-11-04       Impact factor: 3.494

3.  Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells.

Authors:  Shiho Yoshida; Miyuki Murata; Kousuke Noda; Takashi Matsuda; Michiyuki Saito; Wataru Saito; Atsuhiro Kanda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2018-02-01       Impact factor: 2.447

4.  Proteomic analysis of vitreous biopsy techniques.

Authors:  Jessica M Skeie; Eric N Brown; Harryl D Martinez; Stephen R Russell; Emily S Birkholz; James C Folk; H Culver Boldt; Karen M Gehrs; Edwin M Stone; Michael E Wright; Vinit B Mahajan
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

5.  Pathobiochemical changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics.

Authors:  Kay Ohlendieck
Journal:  J Nutr Metab       Date:  2012-02-29

6.  Proteomic insight into the molecular function of the vitreous.

Authors:  Jessica M Skeie; C Nathaniel Roybal; Vinit B Mahajan
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

7.  Proteomic interactions in the mouse vitreous-retina complex.

Authors:  Jessica M Skeie; Vinit B Mahajan
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

8.  Diabetic Retinopathy: Battling the Global Epidemic.

Authors:  Arup Das
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-12-01       Impact factor: 4.799

Review 9.  Proteomic Analyses of Vitreous in Proliferative Diabetic Retinopathy: Prior Studies and Future Outlook.

Authors:  Sarah R Weber; Yuanjun Zhao; Christopher Gates; Jingqun Ma; Felipe da Veiga Leprevost; Venkatesha Basrur; Alexey I Nesvizhskii; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

10.  Proteomics of vitreous humor of patients with exudative age-related macular degeneration.

Authors:  Michael Janusz Koss; Janosch Hoffmann; Nauke Nguyen; Marcel Pfister; Harald Mischak; William Mullen; Holger Husi; Robert Rejdak; Frank Koch; Joachim Jankowski; Katharina Krueger; Thomas Bertelmann; Julie Klein; Joost P Schanstra; Justyna Siwy
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.